Abstract: The present invention provides a 2-OST mutant exhibiting a high activity.

Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

Abstract: The present invention provides a 2-OST mutant exhibiting a high activity.

Abstract: An object of the present invention is to provide a metal oxide particle having a surface modified with a quaternary ammonium group, and a method for producing the particle. The present invention relates to a metal oxide particle having a surface modified with a silyl group and having an aggregation ratio (average particle size measured by dynamic light scattering/average diameter of primary particles measured in an SEM image) of 5.

Abstract: The present invention provides a novel sulfated polysaccharide having anticoagulant activity. Specifically, the present invention provides a polysaccharide that includes a repetitive structure of a disaccharide unit composed of a hexuronic acid (HexA) residue and a ?-D-glucosamine (GlcN) residue and having 13% or higher of a 3-O-sulfation rate in GlcN residues.

Abstract: The present invention provides a 2-OST mutant exhibiting a high activity.

Abstract: A method for producing heparosan is provided. Heparosan is produced by culturing an Escherichia bacterium having a heparosan-producing ability and modified so that expression of one or more genes, such as rbsR, rbsK, rbsB, hsrA, glgB, glgX, micF, rcsD, rcsB, ybiX, ybil, ybiJ, ybiC, ybiB, rfaH, nusG, pcoR, pcoS, pcoE, yhcN, yhcO, aaeB, aaeA, aaeX, g1455, alpA, g1453, yrbA, mlaB, mlaC, mlaD, mlaE, mlaF, yrbG, norW, ybjI, ybjJ, ybjK, rybB, yjjY, yjtD, thrL, thrA, thrB, fruA, psuK, ytfT, yjfF, fbp, yagU, paoA, paoB, gsiC, gsiD, yliE, irp2, irp1, bhsA, ycfS, lepB, rnc, era, dapA, gcvR, bcp, hyfA, rpoE, nadB, yfiC, srmB, g1414, g1413, nuoE, nuoF, nuoG, glmZ, hemY, hemX, hemD, rlmL, artQ, artM, artJ, rlmC, ybjO, yejO, yejM, yejL, rpoS, ygbN, ygbM, ygbL, g3798, g3797, g3796, g3795, g3794, g3793, g3792, ryjA, soxR, soxS, yjcC, yjcB, efeU, and efeO, is/are increased in a medium, and collecting heparosan from the medium.

Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

Abstract: A reflective polarizing film for a liquid crystal display polarizer that has a high polarization performance and eliminates a hue shift at an oblique azimuth of 45°, a polarizer for a liquid crystal display composed of the same, an optical member for a liquid crystal display, and a liquid crystal display are provided. In a reflective polarizing film for a liquid crystal display polarizer composed of a uniaxially stretched multi-layer laminate film in which a first layer and a second layer are alternately laminated, the reflective polarizing film has a polarization degree of 99.5% or more and an amplitude of a transmittance waveform of 2.0% or less in a wavelength range of 450 to 650 nm measured with respect to the polarized light incident at an incident angle of 60° on an incident plane including an azimuth angle of 45°, among polarized light components parallel to the transmission axis.

Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

Abstract: The present invention provides a novel sulfated polysaccharide having anticoagulant activity. Specifically, the present invention provides a polysaccharide that includes a repetitive structure of a disaccharide unit composed of a hexuronic acid (HexA) residue and a ?-D-glucosamine (GlcN) residue and having 13% or higher of a 3-O-sulfation rate in GlcN residues.

Abstract: A method for producing heparosan is provided. Heparosan is produced by culturing an Escherichia bacterium having a heparosan-producing ability and modified so that expression of one or more genes, such as rbsR, rbsK, rbsB, hsrA, glgB, glgX, micF, rcsD, rcsB, ybiX, ybil, ybiJ, ybiC, ybiB, rfaH, nusG, pcoR, pcoS, pcoE, yhcN, yhcO, aaeB, aaeA, aaeX, g1455, alpA, g1453, yrbA, mlaB, mlaC, mlaD, mlaE, mlaF, yrbG, norW, ybjI, ybjJ, ybjK, rybB, yjjY, yjtD, thrL, thrA, thrB, fruA, psuK, ytfT, yjfF, fbp, yagU, paoA, paoB, gsiC, gsiD, yliE, irp2, irp1, bhsA, ycfS, lepB, rnc, era, dapA, gcvR, bcp, hyfA, rpoE, nadB, yfiC, srmB, g1414, g1413, nuoE, nuoF, nuoG, glmZ, hemY, hemX, hemD, rlmL, artQ, artM, artJ, rlmC, ybjO, yejO, yejM, yejL, rpoS, ygbN, ygbM, ygbL, g3798, g3797, g3796, g3795, g3794, g3793, g3792, ryjA, soxR, soxS, yjcC, yjcB, efeU, and efeO, is/are increased in a medium, and collecting heparosan from the medium.

Abstract: Provided is a uniaxially stretched multi-layer laminate film including a first layer and a second layer alternately laminated each other, wherein the first layer is a layer containing a polyester, the polyester containing an ethylene naphthalate unit in an amount of 50 mol % or more and 100 mol % or less on a basis of a repeating unit that constitutes the polyester, and a polymer that forms the second layer is a copolymer polyester containing, as copolymer components, a 2,6-naphthalenedicarboxylic acid component, an ethylene glycol component, and a trimethylene glycol component, (A) the content of an ethylene naphthalate unit in the polyester of the first layer being 80 mol % or more and 100 mol % or less on a basis of the repeating unit that constitutes the polyester, or (B) the polymer that forms the second layer being the copolymer polyester further containing, as a copolymer component, an alicyclic diol component.

Abstract: A method for producing heparosan is provided. Heparosan is produced by culturing an Escherichia bacterium having a heparosan-producing ability and modified so that expression of one or more genes, such as rbsR, rbsK, rbsB, hsrA, glgB, glgX, micF, rcsD, rcsB, ybiX, ybiI, ybiJ, ybiC, ybiB, rfaH, nusG, pcoR, pcoS, pcoE, yhcN, yhcO, aaeB, aaeA, aaeX, g1455, alpA, g1453, yrbA, mlaB, mlaC, mlaD, mlaE, mlaF, yrbG, norW, ybjI, ybjJ, ybjK, rybB, yjjY, yjtD, thrL, thrA, thrB, fruA, psuK, ytfT, yjfF, fbp, yagU, paoA, paoB, gsiC, gsiD, yliE, irp2, irp1, bhsA, ycfS, lepB, rnc, era, dapA, gcvR, bcp, hyfA, rpoE, nadB, yfiC, srmB, g1414, g1413, nuoE, nuoF, nuoG, glmZ, hemY, hemX, hemD, rlmL, artQ, artM, artJ, rlmC, ybjO, yejO, yejM, yejL, rpoS, ygbN, ygbM, ygbL, g3798, g3797, g3796, g3795, g3794, g3793, g3792, ryjA, soxR, soxS, yjcC, yjcB, efeU, and efeO, is/are increased in a medium, and collecting heparosan from the medium.

Abstract: Provided is a uniaxially stretched multi-layer laminate film including a first layer and a second layer alternately laminated each other, wherein the first layer is a layer containing a polyester, the polyester containing an ethylene naphthalate unit in an amount of 50 mol % or more and 100 mol % or less on a basis of a repeating unit that constitutes the polyester, and a polymer that forms the second layer is a copolymer polyester containing, as copolymer components, a 2,6-naphthalenedicarboxylic acid component, an ethylene glycol component, and a trimethylene glycol component, (A) the content of an ethylene naphthalate unit in the polyester of the first layer being 80 mol % or more and 100 mol % or less on a basis of the repeating unit that constitutes the polyester, or (B) the polymer that forms the second layer being the copolymer polyester further containing, as a copolymer component, an alicyclic diol component.

Abstract: A reflective polarizing film for a liquid crystal display polarizer that has a high polarization performance and eliminates a hue shift at an oblique azimuth of 45°, a polarizer for a liquid crystal display composed of the same, an optical member for a liquid crystal display, and a liquid crystal display are provided. In a reflective polarizing film for a liquid crystal display polarizer composed of a uniaxially stretched multi-layer laminate film in which a first layer and a second layer are alternately laminated, the reflective polarizing film has a polarization degree of 99.5% or more and an amplitude of a transmittance waveform of 2.0% or less in a wavelength range of 450 to 650 nm measured with respect to the polarized light incident at an incident angle of 60° on an incident plane including an azimuth angle of 45°, among polarized light components parallel to the transmission axis.

Abstract: A uniaxially stretched multi-layer laminate film that exhibits a high polarization performance of 99.5% or more in a simpler configuration than before, a polarizing plate that is composed of the same, an optical member for a liquid crystal display device, and a liquid crystal display device are provided. Namely, in the uniaxially stretched multi-layer laminate film in which a first layer and a second layer are alternately laminated, the uniaxially stretched multi-layer laminate film includes an intermediate layer that has a thickness of 2 ?m or more and 30 ?m or less; the first layer is composed of a polyester containing a naphthalene dicarboxylic acid ester; the second layer is composed of a copolymer polyester and is an optically isotropic layer that has an average refractive index of 1.50 or more and 1.60 or less; the first layer, the second layer, both first and second layers, or the intermediate layer contains a visible light absorbent, which has a weight loss of less than 10% when it is kept at 300° C.

Abstract: An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.

Abstract: A method for producing heparosan is provided. Heparosan is produced by culturing an Escherichia bacterium having a heparosan-producing ability and modified so that expression of one or more genes, such as rbsR, rbsK, rbsB, hsrA, glgB, glgX, micF, rcsD, rcsB, ybiX, ybiI, ybiJ, ybiC, ybiB, rfaH, nusG, pcoR, pcoS, pcoE, yhcN, yhcO, aaeB, aaeA, aaeX, g1455, alpA, g1453, yrbA, mlaB, mlaC, mlaD, mlaE, mlaF, yrbG, norW, ybjI, ybjJ, ybjK, rybB, yjjY, yjtD, thrL, thrA, thrB, fruA, psuK, ytfT, yjfF, fbp, yagU, paoA, paoB, gsiC, gsiD, yliE, irp2, irp1, bhsA, ycfS, lepB, rnc, era, dapA, gcvR, bcp, hyfA, rpoE, nadB, yfiC, srmB, g1414, g1413, nuoE, nuoF, nuoG, glmZ, hemY, hemX, hemD, rlmL, artQ, artM, artJ, rlmC, ybjO, yejO, yejM, yejL, rpoS, ygbN, ygbM, ygbL, g3798, g3797, g3796, g3795, g3794, g3793, g3792, ryjA, soxR, soxS, yjcC, yjcB, efeU, and efeO, is/are increased in a medium, and collecting heparosan from the medium.

Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.